RFL

Rafael Holdings, Inc. [RFL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RFL Stock Summary

Top 10 Correlated ETFs

RFL

Top 10 Correlated Stocks

RFL

In the News

RFL Financial details

Company Rating
-
Market Cap
39.5M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
11 Jun 2024
P/E
-6.06
Forward P/E
-
PEG
-
P/S
163.67
P/B
0.45
P/C
-
P/FCF
-4.33
Quick Ratio
79.87
Current Ratio
82.94
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-98.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-26.27%
Revenue last 5Y
-43.7%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-8%
ROE
-7%
ROC
-0.13%
Gross Margin
100%
Oper. Margin
-4469%
Profit Margin
-2605%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.44-2.52
52W High
-35.51%
52W Low
+28.98%
RSI
46
Rel Volume
4.15
Avg Volume
25.55K
Volume
106.13K
Perf Week
-12.26%
Perf Month
8.39%
Perf Quarter
-5.16%
Perf Half Y
-3.02%
-
-
-
-
Beta
1.268
-
-
Volatility
0.08%, 0.11%
Prev Close
-2.29%
Price
1.2898
Change
-3.02%

Something similar

Top by Market Cap
AMZ.DE
BRH.DE
ABEC.DE
GOOG
NVD.DE
Top Correlated ETFs
YXI
FAAR
XOP
YANG
FXP
Top Correlated Stocks
AAOI
0HGV.L
UTGN
ERAS
RLYB
Similar Market Cap
CSFS.L
TMKRU
VMOT
LSX.DE
1049.HK

Company Profile

Real Estate Real Estate - Services
  • Volume Average 25.55K
  • Market Capitalization 39.5M
  • Employee 13
  • CEO Mr. William Conkling
  • Headquarters Newark,NJ,US
  • IPO Date 2018-03-27
  • Website https://www.rafaelholdings.com

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.